Recordati Industria Chimica e Farmaceutica SpA REC.MI · EUR
Health Care · Borsa Italiana · 🇮🇹 Italy
53.10
-0.28%
Close of 9 Nov 2026, in EUR
Search any instrument
Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.
About Recordati Industria Chimica e Farmaceutica SpA
Its shares trade on Borsa Italiana under the ticker REC.MI. It has been listed since 1 January 1984. In the fiscal year to 31 December 2025, it reported revenue of €2.62bn and net income of €443.6m. At that date it held total assets of €5.25bn and shareholders' equity of €1.92bn.
Recordati SpA engages in the research, development, manufacturing and marketing of pharmaceuticals. The company is headquartered in Milan, Milano. The company promotes a wide range of pharmaceuticals, both proprietary and under license, in a number of therapeutic areas, such as Antibiotics and Antiviral, Cardiovascular, Central nervous system, Dermatological, Gastroenterology, Genital-urinary system, Muscular-skeletal disorders and pain therapy, Obstetrics and Gynecology and over the counter (OTC) pharmaceuticals. The firm is engaged in the research and development of new drug entities within the cardiovascular and urogenital therapeutic areas and of treatments for rare diseases. It’s product is ZANIDIP, a latest generation calcium-channel blocker for the treatment hypertension. The company operates through Italchimici SpA, Pro Farma AG and North American marketing rights to Cystadane. The firm owns and operates through Natural Point srl also in the food supplement sector.
Figures and description from our data supplier, not checked against the company's own report.
Company facts
- Sector
- Health Care
- Industry
- Pharmaceuticals
- Listed since
- 1 Jan 1984
- Employees
- 4,323
- Website
- recordati.com ↗
Leadership
Pay as last reported
- Dr. Andrea RecordatiNon-Executive Chairman of the Board, since 2002€300,000
- Dr. Robert KoremansChief Executive Officer, Executive Director, since 2021€2.3m
- Mr. Guido GuidiNon-Executive Vice Chairman of the Board€90,000
- Mr. Luigi CorteChief Financial Officer, Executive Director, since 2020€1.5m
- Ms. Alessandra AbateGroup Chief People and Culture Officer
- Mr. Gabriele FinziExecutive Vice President - Corporate Development, Licensing and Innovation
- Mr. Alessandro GilioExecutive Vice President - Group Industrial Operations
- Mr. Alberto MartinezExecutive Vice President - Specialty and Primary Care Business Unit
- Mr. Scott PescatoreExecutive Vice President - Rare Disease Business Unit
- Mr. Milan ZdravkovicExecutive Vice President - Research and Development
- Mr. Niccolo GiovanniniVice President - Finance
- Mr. Giorgio De PalmaExecutive Director, since 2020
Environmental, social and governance
Scores out of 100, from our data supplier
- Overall
- 87
- Environment
- 98
- Social
- 99
- Governance
- 62
- Direct emissions (scope 1)
- 36,607 t
- Energy emissions (scope 2)
- 9,811 t
- Women in the workforce
- 49%
- Carbon reduction policy
- Yes
- Human rights policy
- Yes
SWOT analysis
AI-generated by our data supplier. Not written or checked by our editors.
Strengths
- Recordati Industria Chimica e Farmaceutica SpA has several strengths that contribute to its success in the market. Firstly, the company has a strong brand reputation built over its long history of more than 90 years in the pharmaceutical industry. This positions it as a trusted and reliable provider of pharmaceutical products.
- Another strength of Recordati is its broad and diverse product portfolio. The company offers a range of therapeutic solutions across various therapeutic areas, enabling it to cater to a wide customer base. This diversity helps reduce dependence on a single product or market segment.
- Additionally, Recordati benefits from its strong research and development capabilities. The company invests in innovative research, ensuring the continuous development of new drugs and improving existing ones. This keeps Recordati at the forefront of pharmaceutical advancements.
Weaknesses
- Despite its strengths, Recordati also faces certain weaknesses that require attention. One weakness is the company's limited geographic presence. While it operates globally, its presence in certain regions is relatively weaker compared to its competitors. This restricts its market reach and potential growth opportunities.
- Another weakness lies in the company's heavy reliance on a few key products for a significant portion of its revenue. The success of these products is crucial for Recordati's financial performance, creating vulnerability if competition or market conditions impact their sales.
Opportunities
- Recordati has several opportunities that can be leveraged to its advantage. Firstly, the global pharmaceutical market is experiencing strong growth, driven by factors such as an aging population and increasing healthcare expenditure. By capitalizing on this trend, Recordati can expand its customer base and boost revenues.
- Another opportunity lies in the expansion into emerging markets. These regions offer untapped potential and a growing demand for pharmaceutical products. By establishing a stronger presence in these markets, Recordati can diversify its revenue streams and minimize the impact of market-specific challenges.
Threats
- Recordati, like any other pharmaceutical company, faces several threats in its operating environment. One significant threat is the intense competition within the industry. The pharmaceutical sector is highly competitive, with numerous companies vying for market share. This can lead to price wars, erosion of profit margins, and the need to constantly innovate to stay ahead.
- Another threat is the stringent regulatory environment governing the pharmaceutical industry. Compliance with regulations and the need for drug approvals can be time-consuming and costly. Non-compliance or delays in obtaining approvals can negatively impact the company's operations and financial performance.
Sources and methodology
- Data on this tab
- Our data supplier
- Chart on the Overview
- TradingView
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.